Discontinued — last reported Q4 '25
Edwards Lifesciences Other Non-Current Assets increased by 0.6% to $16.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 18.0%, from $20.50M to $16.80M. Over 2 years (FY 2023 to FY 2025), Other Non-Current Assets shows an upward trend with a 9.2% CAGR.
Large fluctuations may relate to changes in long-term investment strategy or tax accounting adjustments.
A catch-all category for long-term assets that do not fit into major classifications like PPE or Intangibles. This may i...
Often contains strategic minority investments in technology partners or long-term tax-related items.
other_non_current_assets| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.00M | $13.90M | $14.40M | $13.90M | $15.00M | $20.50M | $27.30M | $22.90M | $16.70M | $16.80M |
| QoQ Change | — | -0.7% | +3.6% | -3.5% | +7.9% | +36.7% | +33.2% | -16.1% | -27.1% | +0.6% |
| YoY Change | — | — | — | — | +7.1% | +47.5% | +89.6% | +64.7% | +11.3% | -18.0% |